[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353881-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353881-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","oncostatin-m-ligand-based-car-t-therapy-displays-robust-anti-tumor-activity-against-osteosarcoma","Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma","","CAR-T therapy has transformed many hematologic malignancies but remains less effective for solid tumors like osteosarcoma, where antigen heterogeneity can limit targeting. This study evaluates a ligand-based CAR-T strategy that uses oncostatin M to engage multiple receptor targets. Oncostatin M, its receptor OSMR, and/or LIFR show high expression in osteosarcoma cell lines and patient samples, supporting assessment of OSM ligand-based CAR-T cells as a therapeutic option.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/oncostatin-m-ligand-based-car-t-therapy-displays-robust-anti-tumor-activity-against-osteosarcoma/353881/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/oncostatin-m-ligand-based-car-t-therapy-displays-robust-anti-tumor-activity-against-osteosarcoma/353881.png","ImageObject",300,407,{"name":42,"@type":43},"Rhys","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why might CAR-T therapy be less effective against solid tumors such as osteosarcoma?","Question",{"text":63,"@type":64},"Lower efficacy is linked to increased antigen heterogeneity in solid tumors, which can limit consistent targeting. The article also notes that CAR-T killing mechanisms differ between solid and liquid cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What ligand-based CAR-T approach does the study investigate?",{"text":68,"@type":64},"The study uses third-generation CAR-T cells expressing human oncostatin M on their surface, enabling targeting of multiple receptors via a single ligand. Receptor expression (OSMR and LIFR) and susceptibility are tested in patient-derived samples.",{"name":70,"@type":61,"acceptedAnswer":71},"What anti-tumor effects are reported for OSM ligand-based CAR-T cells?",{"text":72,"@type":64},"OSM-CAR-T cells show target-specific cytotoxicity against osteosarcoma cell lines and patient samples in vitro and in vivo. Single intravenous dosing reduces tumor burden in multiple mouse xenograft and metastatic models, alongside increased cytokine release such as IFNγ.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353881,1790371836,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Feinberg etal. BMC Medicine (2026) 24:158 [https://doi.org/10.1186/s12916-026-04729-8](https://doi.org/10.1186/s12916-026-04729-8)  \nBMC Medicine  \n RESEARCH Open Access  \nOncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma  \nDaniel Feinberg1, Vinayak Uppin2, Saada Eid3, Claire Fritz 1, Masahiro Hitomi4,5, Akshaya Radhakrishnan2, Kayla Klatt1, Sung Hee Choi3,6, Jay T Myers3, Aarshvi Bhatt2, Duncan Stearns3,7, Irina Pateva3,7, Zachary D C Burke4,8, Alex Y Huang1,3,6,7,9, Gary K Schwartz6 and Reshmi Parameswaran 1,2,6,7*  \nAbstract  \nBackground CAR-T therapy has revolutionized treatments for many hematologic malignancies, but it has shown far less efficacy against solid tumors. One reason for this lower efficacy in solid tumors is increased antigen heterogeneity. This study utilizes a ligand-based CAR-T approach, which allows targeting of multiple receptors by a single ligand. A high expression of the ligand oncostatin M’s (OSM) receptors, oncostatin M receptor (OSMR), and/or leukemic inhibitory factor receptor (LIFR) were noted in osteosarcoma cell lines and patient samples. Osteosarcoma is a bone cancer where treatment options have been stagnant for close to 40 years. Thus, this study explores the therapeutic potential of OSM ligand-based CAR-T cells against osteosarcoma.  \nMethods Third-generation CAR-T cells expressing human OSM on their surface were created, with the surface expression of OSM confirmed by flow cytometry. Co-incubation of OSM CARs and osteosarcoma in vitro was performed, with cell death assessed via Incucyte and PI detection by flow cytometry. CAR-Ts were injected i.v. into mice with osteosarcoma cell line xenografts, and metastatic osteosarcoma. New patient-derived samples were tested for OSMR and LIFR expression and vulnerability to OSM CART cells. A new PDX model (named KKOS) from a patient with metastatic treatment-resistant osteosarcoma was characterized and tested for its susceptibility to OSM CART cells. All cytotoxic in vivo experiments were performed with n=3–6 mice per group per experiment.  \nResults OSM-CAR-T cells displayed cytotoxicity against osteosarcoma cell lines and patient samples expressing either one of OSM’s receptors in vitro and in vivo. Large increases in cytokine release, specifically IFNγ, were noted in a target-specific manner. One injection of OSM-CAR-T cells intravenously reduced tumor burden in two different mouse xenograft models. A similar anti-tumor effect was also noted in a metastatic model and a mouse model with multiple implanted KKOS tumors.  \nConclusions Human ligand-based OSM CAR-T cells displayed anti-tumor effects against multiple osteosarcoma cell lines and patient samples. These effects were demonstrated in vitro, in xenograft models, and against a model simulating metastatic disease. Overall, this data supports the continued study of OSM-CAR-T cells as a new therapeutic avenue for osteosarcoma.  \nKeywords CAR-T, Osteosarcoma, Oncostatin-M (OSM), Immunotherapy, OSMR, LIFR  \n*Correspondence: Reshmi Parameswaran [rxp278@case.edu](rxp278@case.edu)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is ","cbCaiijBwVnIPajq","https://ap.wps.com/l/cbCaiijBwVnIPajq","pdf",9129798,18,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n## Keywords\n# Background\n## Clinical context in osteosarcoma\n## Immunotherapy and CAR-T therapy challenges","[{\"question\":\"Why might CAR-T therapy be less effective against solid tumors such as osteosarcoma?\",\"answer\":\"Lower efficacy is linked to increased antigen heterogeneity in solid tumors, which can limit consistent targeting. The article also notes that CAR-T killing mechanisms differ between solid and liquid cancers.\"},{\"question\":\"What ligand-based CAR-T approach does the study investigate?\",\"answer\":\"The study uses third-generation CAR-T cells expressing human oncostatin M on their surface, enabling targeting of multiple receptors via a single ligand. Receptor expression (OSMR and LIFR) and susceptibility are tested in patient-derived samples.\"},{\"question\":\"What anti-tumor effects are reported for OSM ligand-based CAR-T cells?\",\"answer\":\"OSM-CAR-T cells show target-specific cytotoxicity against osteosarcoma cell lines and patient samples in vitro and in vivo. Single intravenous dosing reduces tumor burden in multiple mouse xenograft and metastatic models, alongside increased cytokine release such as IFNγ.\"}]","Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma | PDF",1790107729,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28972bcf5e24840579181fdcb4cdd696.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8078e67d7c021a384422475759c92cb6.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d18eb45ad0571858b73d11a573afabf6.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3de0b88ee83cbf55c51b0f4b3ced9db.webp",980,1301]